Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Stifel Downgrades Imago BioSciences to Hold, Raises Price Target to $36

Stifel Downgrades Imago BioSciences to Hold, Raises Price Target to $36

Stifel analyst Stephen Willey downgrades Imago BioSciences (NASDAQ:IMGO) from Buy to Hold and raises the price target from $35 to $36.

byBenzinga Newsdesk

November 28, 2022

1 minute read

Stifel analyst Stephen Willey downgrades Imago BioSciences (NASDAQ:IMGO) from Buy to Hold and raises the price target from $35 to $36.

B of A Securities Maintains Buy on Workday, Raises Price Target to $220

By Benzinga Newsdesk

February 22, 11:03 AM

B of A Securities analyst Brad Sills maintains Workday (NASDAQ:WDAY) with a Buy and raises the price target from $200 to $220.

WDAY

Banco Santander Chile Q4 EPS $0.25 Misses $0.31 Estimate, Sales $415.68M Miss $627.38M Estimate

By Benzinga Newsdesk

February 3, 8:37 AM

Banco Santander Chile (NYSE:BSAC) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.31 by 19.35 percent. This is a 56.9 percent decrease over earnings of $0.58 per share

BSAC

News
Tech

Tesla Model Y Price Cuts Continue In Canada — The Priciest Model To Now Cost 5.8% Less

By Anan Ashraf

February 7, 12:00 AM

Tesla Inc (NASDAQ:TSLA) has cut prices on its costliest Model Y version in Canada, days after the company…

TSLA

Mizuho Maintains Buy on Syneos Health, Lowers Price Target to $87

By Benzinga Newsdesk

August 3, 11:07 AM

Mizuho analyst Ann Hynes maintains Syneos Health (NASDAQ:SYNH) with a Buy and lowers the price target from $94 to $87.

SYNH

Stifel Downgrades Imago BioSciences to Hold, Raises Price Target to $36

Related Posts

B of A Securities Maintains Buy on Workday, Raises Price Target to $220

Banco Santander Chile Q4 EPS $0.25 Misses $0.31 Estimate, Sales $415.68M Miss $627.38M Estimate

Tesla Model Y Price Cuts Continue In Canada — The Priciest Model To Now Cost 5.8% Less

Mizuho Maintains Buy on Syneos Health, Lowers Price Target to $87